Technologies

Mesoblast’s cell-based core technologies include its highly purified, immunoselected Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Mesoblast’s protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1).

Mesoblast is developing a range of products derived from the Company’s proprietary Mesenchymal Cell Lineage technology platforms. Mesoblast’s product development focus is in four major and distinct areas:

• systemic diseases with an underlying inflammatory and immunologic etiology
• cardiac and vascular diseases
• orthopedic diseases of the spine
• improving outcomes of bone marrow transplantation